PSCA and MUC1 in non-small-cell lung cancer as targets of chimeric antigen receptor T cells

CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date

(2016) Jae H. Park et al.   BLOOD

Review: Current clinical applications of chimeric antigen receptor (CAR) modified T cells

(2016) Mark B. Geyer et al.   CYTOTHERAPY

Histologic and molecular analysis of patient derived xenografts of high-grade serous ovarian carcinoma

(2016) Ruifen Dong et al.   Journal of Hematology & Oncology

Second- and third-generation ALK inhibitors for non-small cell lung cancer

(2016) Jingjing Wu et al.   Journal of Hematology & Oncology

Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer

(2016) Shuhang Wang et al.   Journal of Hematology & Oncology

Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy

(2016) Weijie Ma et al.   Journal of Hematology & Oncology

EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer

(2016) Shuhang Wang et al.   Journal of Hematology & Oncology

Immune biomarkers of treatment failure for a patient on a phase I clinical trial of pembrolizumab plus radiotherapy

(2016) Gregory S. Alexander et al.   Journal of Hematology & Oncology

Prospects for gene-engineered T cell immunotherapy for solid cancers

(2016) Christopher A Klebanoff et al.   NATURE MEDICINE

Driving CAR T-cells forward

(2016) Hollie J. Jackson et al.   Nature Reviews Clinical Oncology

Chimeric antigen receptor-modified T cells for the treatment of solid tumors: Defining the challenges and next steps

(2016) Gregory L. Beatty et al.   PHARMACOLOGY & THERAPEUTICS

Treatment of solid tumors with chimeric antigen receptor-engineered T cells: current status and future prospects

(2016) Shengmeng Di et al.   Science China-Life Sciences

Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer

(2016) Kaichao Feng et al.   Science China-Life Sciences

Mechanisms of immune evasion and current status of checkpoint inhibitors in non-small cell lung cancer

(2016) Angel Qin et al.   Cancer Medicine

Eradication of B-ALL using chimeric antigen receptor-expressing T cells targeting the TSLPR oncoprotein

(2015) H. Qin et al.   BLOOD

Global cancer statistics, 2012

(2015) Lindsey A. Torre et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancer

(2015) Thu Oanh Dang et al.   Expert Review of Anticancer Therapy

Quantitative evaluation of the immunodeficiency of a mouse strain by tumor engraftments

(2015) Wei Ye et al.   Journal of Hematology & Oncology

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M

(2015) Kenneth S Thress et al.   NATURE MEDICINE

4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors

(2015) Adrienne H Long et al.   NATURE MEDICINE

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

(2015) Edward B. Garon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

(2015) Julie Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Expression of stem cell markers nanog and PSCA in gastric cancer and its significance

(2015) XUANZHONG ZHAO et al.   Oncology Letters

Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors

(2015) A. Morello et al.   Cancer Discovery

Adoptive immunotherapy using T lymphocytes redirected to glypican-3 for the treatment of lung squamous cell carcinoma

(2015) Kesang Li et al.   Oncotarget

Cellular Immunotherapy for Carcinoma Using Genetically Modified EGFR-Specific T Lymphocytes

(2015) Xikun Zhou et al.   NEOPLASIA

Systemic treatment with CAR-engineered T cells against PSCA delays subcutaneous tumor growth and prolongs survival of mice

(2014) Victoria Hillerdal et al.   BMC CANCER

Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia

(2014) C. O'Hear et al.   HAEMATOLOGICA

A Novel Chimeric Antigen Receptor Against Prostate Stem Cell Antigen Mediates Tumor Destruction in a Humanized Mouse Model of Pancreatic Cancer

(2014) Daniel Abate-Daga et al.   HUMAN GENE THERAPY

Retargeting of Human T Cells to Tumor-Associated MUC1: The Evolution of a Chimeric Antigen Receptor

(2014) S. Wilkie et al.   JOURNAL OF IMMUNOLOGY

Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research

(2014) M. Hidalgo et al.   Cancer Discovery

Interleukin-7 Mediates Selective Expansion of Tumor-redirected Cytotoxic T Lymphocytes (CTLs) without Enhancement of Regulatory T-cell Inhibition

(2013) S. K. Perna et al.   CLINICAL CANCER RESEARCH

Antitumor Effects of Chimeric Receptor Engineered Human T Cells Directed to Tumor Stroma

(2013) Sunitha Kakarla et al.   MOLECULAR THERAPY

PSCA and Oct-4 Expression in the Benign and Malignant Lesions of Gallbladder: Implication for Carcinogenesis, Progression, and Prognosis of Gallbladder Adenocarcinoma

(2013) Qiong Zou et al.   Biomed Research International

Interleukin 15 Provides Relief to CTLs from Regulatory T Cell-Mediated Inhibition: Implications for Adoptive T Cell-Based Therapies for Lymphoma

(2012) S. K. Perna et al.   CLINICAL CANCER RESEARCH

MUC1 glycopeptide epitopes predicted by computational glycomics

(2012) WEI SONG et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Dual Targeting of ErbB2 and MUC1 in Breast Cancer Using Chimeric Antigen Receptors Engineered to Provide Complementary Signaling

(2012) Scott Wilkie et al.   JOURNAL OF CLINICAL IMMUNOLOGY

Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells

(2012) Christopher C Kloss et al.   NATURE BIOTECHNOLOGY

OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4+T cells

(2012) Andreas A. Hombach et al.   OncoImmunology

CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo

(2011) D.-G. Song et al.   BLOOD

Global cancer statistics

(2011) Ahmedin Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

IL-7 and IL-21 are superior to IL-2 and IL-15 in promoting human T cell-mediated rejection of systemic lymphoma in immunodeficient mice

(2010) J. C. Markley et al.   BLOOD

Clinical Significance of Prostate Stem Cell Antigen Expression in Non-small Cell Lung Cancer

(2010) Takeshi Kawaguchi et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety

(2010) V Hoyos et al.   LEUKEMIA

Expression and prognostic relevance of MUC1 in stage IB non-small cell lung cancer

(2010) Dongrong Situ et al.   MEDICAL ONCOLOGY